The risk factors and preventive measures for the recurrence of endometrial polyps


  • Nitisha Doobaly Department of Obstetrics and Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China
  • Xiuli Wang Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China
  • Minjuan Lin Department of Obstetrics and Gynecology,The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China
  • Shu Zhu Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China
  • Xia Wang Department of Obstetrics and Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China



Contraceptives, Endometrial polyps, Hysteroscopy, Recurrence


Endometrial polyps (EPs) are a frequently encountered gynecologic disease with abnormal uterine bleeding and infertility being the two common presenting problems, and hysteroscopic polypectomy is an effective method to remove them. The postoperative polyp recurrence might result in reappearance of abnormal uterine bleeding or infertility, whereas factors influencing the postoperative recurrence potential have limited data. Endometrial polyp recurrence remains a concern with recurrence rates of 2.5% to 43.6%. As such, it is critical to identify the risk factors and the preventive measures for endometrial recurrence, especially in reproductive-age women desiring future conception, to aid in clinical counselling and decision making. The recurrence of EPs is related to estrogen stimulation and endometrial hyperplasia. The progesterone-containing drugs are currently the most commonly used method to prevent the recurrence of EPs. In this article, authors aim to discuss the high-risk factors of EPs recurrence and the preventive measures for EPs recurrence. The preventive measures will focus on the combined oral contraceptives (COCs) and the levonorgestrel-releasing intrauterine system (LNG-IUS).


Savelli L, De Iaco P, Santini D, Rosati F, Ghi T, Pignotti E, et al. Histopathologic features and risk factors for benignity, hyperplasia, and cancer in EPs. Am J Obstet Gynecol. 2003;188:927-31.

DeWaay DJ, Syrop CH, Nygaard IE, Davis WA, Van Voorhis BJ. Natural history of uterine polyps and leiomyomata. Obstet Gynecol. 2002;100:3-7.

Orovieto R, Bar-Hava I, Dicker D, Bar J, Ben-Rafael Z, Nezi A. EPs during menopause: characterization and significance. Acta Obstet Gynecol Scand. 1999;78:883-6.

Golan A, Cohen-Sahar B, Keidar R, Confrea A, Ginath S, Sagiv R. EPs: symptomatology, menopausal status and malignancy. Gynecol Obstet Invest. 2010;70:107-12.

Varasteh NN, Neuwirth RS, Levin B, Keltz MD. Pregnancy rates after hysteroscopic polypectomy and myomectomy in infertile women. Obstet Gynecol. 1999;94:168-71.

Hosseini MA, Ebrahimi N, Mahdavi A, Aleyasin A, Safdarian L, Fallahi P, et al. Hysteroscopy in patients with repeated implantation failure improves the outcome of assisted reproductive technology in fresh and frozen cycles. J Obstet Gynaecol Res. 2014;40:1324-30.

Paradisi R, Rossi S, Scifo MC, Dall’O’F, Battaglia C, Venturoli S. Recurrence of EPs. Gynecol Obstet Invest. 2014;78:26-32.

Preutthipan S, Herabutya Y. Hysteroscopic polypectomy in 240 premenopausal and postmenopausal women. Fertil Steril. 2005;83:705-9.

Yang JH, Chen CD, Chen SU, Yang YS, Chen MJ. Factors influencing the recurrence potential of benign EPs after hysteroscopic polypectomy. PLoS One. 2015;10:e0144857.

Gao W, Zhang L, Li W, Li J, Wang W, Zhao W, et al. Three-year follow-up results of polypectomy with endometrial ablation in the management of EPs with tamoxifen in Chinese women. Eur J Ob-stet Gynecol Reprod Biol. 2012;161:62-5.

Gu F, Zhang H, Ruan S, Li J, Liu X, Xu Y, et al. High number of endometrial polyps is a strong predictor of recurrence: findings of a prospective cohort study in reproductive-aged women. Fertil Steril. 2018;109:493-500.

Taylor E, Gomel V. The uterus and fertility. Fertil Steril. 2008;89:1-16.

Ebauer G, Hafner A, Siebzehnrübl E, Lang N. Role of hysteroscopy in detection and extraction of EPs: results of a prospective study. Am J Obstet Gynecol. 2001:184:59-63.

Henriquez DD, vanDongen H, Wolterbeek R, Jansen FN. Polypectomy in premenopausal women with abnormal uterine bleeding: effectiveness of hysteroscopic removal. J Minim Invasive Gynecol. 2007;14:59-63.

AlHilli MM, Nixon KE, Hopkins MR, Weaver AL, Laughlin-Tommaso SK, Famuyide AO. Long-term outcomes after intrauterine morcellation vs. hysteroscopic resection of endometrial polyps. J Minim Invasive Gynecol. 2013;20:215-21.

Biron-Shental T, Tepper R, Fisheman A, Shapira J, Cohen I. Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen. Gynecol Oncol. 2003;90(2):382-6.

Banas T, Basta P, Knafel A, Skotniczny K, Jach R, Hajdyla-Banas I, et al. DFF45 expression in human endometrium is associated with menstrual cycle phases and decreases after menopause. Gynecol Obstet Invest. 2012;73:177-82.

Torrijos MC, de Merlo GG, Mirasol EG, García MT, Parra CÁ, Goy EI. Endometrial study in patients with postmenopausal metrorrhagia. Arch Med Sci. 2016;12:597-602.

Maja JH, Barbosa IC, Marques D, Calmon LC, Ladipo LC, Coutinho EM. Hysteroscopy and transvaginal sonography in menopausal women receiving hormone replacement therapy. J Am Assoc Gynecol Laparose. 1996;4:1318.

Cheng W-f, Lin H-H, Trong P-L, Huang S-C. Comparison of endometrial changes among symptomatic tamoxifen-treated and non-treated premenopausal and postmenopausal breast cancer patients. Gynaecol Oncol. 1997;66:233-7.

Reslova T, Tonsor J, Resi M, Kugler R, Vavrova I. Endometrial polyps-A clinical study of 245 cases. Arch Gynecol Obstet. 1999;262:3Z.

Vercellini P, Trespidi L, Bramante T, Panazza S, Mauro F, Crosignani PG. Gonadotropin-releasing hormone agonist treatment before hysteroscopic endometrial resection. Int J Gynaecol Obstet. 1994;45:235-9.

Oguz S, Sargin A, Kelekci S, Aytan H, Tapisiz OL, Mollamahmutoglu L. The role of hormone replacement therapy in endometrial polyp formation. Maturitas. 2005;50:231-6.

Wada-Hiraike O, Osuga Y, Hiroi H, Fujimoto A, Maruyama M, Yano T, et al. Sessile polyps and pedunculated polyps respond differently to oral contraceptives. Gynecol Endocrinol. 2011;27(5):351-5.

Stoddard A, McNicholas C, Peipert JF. Efficacy and safety of long-acting reversible contraception. Drugs. 2011;71(8):969-80.

Sivin I, Stern J, Coutinho E, Mattos CE, El Mahgoub S, Diaz S, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the copper T380 Ag IUDS. Contraception. 1991;44(5):473-80.

National Institute for Health and Care Excellence. Long-acting reversible contraception. In: National Institute for health and care excellence, ed. Clinical guidelines; 2014.

American College of Obstetricians and Gynecologists. Noncontraceptive uses of hormonal contraceptives. ACOG Practice Bulletin No. 110. Obstet Gynecol. 2010;115(1):206-18.

Bahamondes L, Ribeiro-Huguet P, Andrade KC, Leon-Martins O, Petta CA. Levonorgestrel-releasing intrauterine system (Mirena) as a therapy for endometrial hyperplasia and carcinoma. Acta Obstet Gynecol Scand. 2003;82(6):580-2.

Barrington JW, Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol. 1997;104:614-6.

Whiteman MK, Zapata LB, Tepper NK, Marchbanks PA, Curtis KM. Use of contraceptive method among women with endometrial hyperplasia: a systematic review. Contracept. 2010;82:56-63.

Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-717.

Neven P, De Muylder X, Van Belle Y, Van-Hooff I, Vanderick G. Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet. 1998;351:36.

Vosse M, Renard F, Coibion M, Neven P, Nogaret JM, Hertens D. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring. Eur J Obstet Gynecol Reprod Biol. 2002;101:58-63.

Ozsemer S, Ozaran A, Itil I, Dikmen Y. Endometrial pathology of 104 postmenopausal breast cancer patients treated with tamoxifen. Eur J Gynaecol Oncol. 1998;19:580-3.

Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. 2009;4:CD007245.

Gardner FJ, Konje JC, Abrams KR, Brown LJ, Khanna S, AL-Azzawi, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet. 2000;356:1711-7.

Gardner FJ, Konje JC, Bell SC, Abrams KR, Brown LJ, Taylor DJ, et al. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial. Gynecol Oncol. 2009;114:452-6.

Wong AW, Chan SS, Yeo W, Yu MY, Tam WH. Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial. Obstet Gynecol. 2013;121:943-50.

Arnes M, Hvingel B, Orbo A. Levonorgestrel-impregnated intrauterine device reduces occurrence of hyperplastic polyps: a population-based follow-up cohort study. Anticancer Res. 2014;34:2319-24.






Review Articles